在当前科学育儿理念日益深入人心的背景下，"临床验证"已成为衡量儿童健康产品品质的关键标准。尤 其是在儿童成长的关键阶段，补钙产品的安全性与有效性更需要强有力的临床研究支持。然而，目前市 场上仍有大量产品停留在"概念宣传"层面，缺乏真实的临床证据，使家长难以甄别和选择真正有效的产 品。 2025年7月16日，CBME国际孕婴童展在上海国家会展中心隆重启幕。来自德国的儿童营养品牌inne因 你不仅展示了全面升级的产品线，更在展会首日举办了以"临床实证：跨时代科学补钙"为主题的学术论 坛。会上，inne携手多位行业专家与学者，首次系统性地发布其全球临床验证体系，推动儿童营养领域 从"经验导向"迈向"科学实证"的全新发展阶段，树立行业新标杆。 央视对此次学术会议进行了重点报道，聚焦inne在儿童补钙临床研究上的突破性成果。此次学术会议打 响了儿童营养领域科学实证的第一枪，推动行业跨入以临床实证为核心的"跨时代"新阶段，不仅为消费 者建立起基于临床实证的科学选钙新标准，更为行业树立了产品功效验证的标杆，带动产业向更科学、 更高质量的方向进阶。 从以"可以直接喝的真正液体钙"破解钙片、胶囊钙的吸收难题，引领行业"吸收革命 ...

在益生菌市场，临床验证的权威性直接转化为消费者的购买决策力。国际品牌的成功经验早已印证临床 验证的市场价值。以Culturelle为例，其明星菌株LGG凭借300余项临床研究，长期稳居全球益生菌销量 榜首；雀巢生命花园则通过LGG菌株改善肠道功能的临床数据，打造出年销售额超10亿美元的大单 品。这些案例表明，临床数据不仅是功效的"科学身份证"，更是品牌建立市场护城河的关键。而这一趋 势在国内市场同样显著，合生元小蓝帽儿童益生菌因搭载经22项临床实证，连续5年位列电商平台品类 前三（来源：天猫健康数据），直观展现了消费者对实证功效的追捧。 （图片来源：淘宝） 而微康益生菌的嗜黏蛋白阿克曼菌Akk11基于5项临床研究、5篇SCI论文及8项发明专利的科研积累，通 过全基因组测序（WGS）与流式细胞计数技术实现菌株纯度与活性的精准控制，活菌规格稳定在6000 亿AFU/g，灭活菌突破10000亿TFU/g的行业高标准。凭借美国FDA-GRAS认证Akk11以200吨年产能的 规模化优势，为代谢健康领域提供高活性、可溯源的解决方案，成为益生菌从科研到产业化的标杆实 践。 微康其建立的"菌株筛选—临床验证—产业化应用"闭 ...

Core Insights - The probiotic market has seen significant growth, but the effectiveness of probiotics is determined by rigorous clinical validation rather than marketing claims about strain variety and high live bacteria counts [1][11] - The World Health Organization (WHO) defines probiotics as live microorganisms that confer health benefits when consumed in adequate amounts, emphasizing strain specificity and dose dependency [1][11] Clinical Validation Advantages - Precision targeting through genomic screening of functionally defined strains, such as Bifidobacterium animalis ssp. lactis BB-12, which has been shown to regulate the gut-immune axis and reduce diarrhea incidence in infants [3] - Safety assurance from clinical trials that can identify potential risks, such as infection risks in immunocompromised individuals or antibiotic resistance issues [3] - Scientific dosing to prevent ineffectiveness from insufficient doses or imbalances from excessive amounts [3] Market Competitiveness - Clinically validated strains have become a "hard currency" in the market, with notable examples including: - Lactobacillus rhamnosus GG, which has over 300 studies confirming its ability to shorten the duration of acute diarrhea in children by 26% and reduce antibiotic-associated diarrhea risk [5] - Bifidobacterium animalis ssp. lactis BB-12, which reduced diarrhea incidence from 42% to 26% during antibiotic treatment and is featured in Puractive's children's probiotic products [7] - Weizmannia coagulans BC99, included in products like Yili's "explosion pearl yogurt," which has shown to improve gut barrier function and regulate immunity [8] Market Challenges - Despite the probiotic market exceeding 100 billion, there are significant issues with product quality, including: - Ambiguous strain sources that may not adapt to the gut environment [12] - Exaggerated claims without clinical support, such as weight loss or anti-aging benefits [12] - Concerns over viability due to improper storage and transport conditions [12] - True clinical probiotics require a comprehensive investment in the entire process from strain selection to safety evaluation, as exemplified by the development of Lactobacillus Zhang, which took nearly ten years to validate its cholesterol-lowering effects [12] Consumer Awareness - The healthy development of probiotics relies on consumer education, focusing on: - Strain identification, ensuring traceability to clinical studies [15] - Live bacteria counts, typically needing to reach 10^8 to 10^12 CFU per day [15] - Formulation and storage methods that enhance live bacteria survival [15] - The future of probiotics will likely see advancements with next-generation strains, but the principle of "no scientific evidence equals ineffective supplementation" remains crucial [15]